Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...

Report Ocean has published a new report on the Saudi Arabia Pompe Disease Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report ...

Maze Therapeutics, Inc.’s MAZE share price has surged by 11.03%, which has investors questioning if this is right time to ...

GAA is responsible for metabolising glycogen, which builds up in Pompe disease patients and causes progressive muscular degeneration. The initial readout will be a relief to Astellas, as AT845 ...

The US regulator has approved Nexviazyme (avalglucosidase alfa) for the treatment of patients aged one year of age and older with late-onset Pompe disease, which progressively attacks the heart ...

The global isovaleric acidemia treatment market is poised for remarkable growth, projected to rise from USD 652.28 million in 2023 to USD 1,125.15 million by 2033, reflecting a robust CAGR of 5.6%.

Analysts are estimating that Amicus Therapeutics will report an earnings per share (EPS) of $0.08. The announcement from Amicus Therapeutics is eagerly anticipated, with investors seeking news of ...

The role of biomarkers in diagnosis, severity assessment, treatment response, and prognosis in patients with lysosomal diseases ... such as pulmonary function tests (in Pompe disease and ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

SEATTLE — There's new hope for people in the early stages of Alzheimer's disease. A new medication called donanemab appears to slow memory loss, giving patients the gift of more time.